Objective To clarify the clinical characteristics and epidemiology of idiopathic pulmonary arterial hypertension (IPAH) in childhood, a rare condition with a bad prognosis, poorly documented in children. Also, to describe the long-term outcome.
Design A retrospective study of 7 years' experience.
Setting UK Service for Pulmonary Hypertension in Children based at a tertiary referral centre.
Patients 64 children.
Interventions Patients were initially treated with prostanoids (n=15), bosentan (n=23), sildenafil (n=9), combination therapy (n=11) or calcium channel antagonists (n=6).
Main outcome measures WHO functional class, distance walked in 6 minutes, escalation of therapy, survival, transplant-free survival.
Results Incidence of IPAH was 0.48 cases per million children per year and the prevalence was 2.1 cases per million. 31% presented with syncope. Oedema was rare. During the first year of follow-up WHO functional class and 6-minute walk distance improved significantly. Survival at 1, 3 and 5 years was 89%, 84% and 75%, respectively; while transplant-free survival was 89% 76% and 57%, respectively. Factors predicting worse survival were WHO functional class (HR 2.4, p=0.04) and poor height and weight z-score (p<0.05 for both) at presentation.
Conclusions We showed, for the first time, that the incidence of IPAH is lower in children than adults and that the clinical features can be different. Most children present with clinical evidence of advanced disease and clinical status at presentation is predictive of outcome. This 7-year experience confirms the significant improvement in survival over historical controls.
- Hypertension, pulmonary
- paediatrics, epidemiology
- paediatric cardiology
- pulmonary arterial hypertension (PAH)
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.
Linked articles 195248.
Funding SM is supported by a grant from the Pulmonary Hypertension Association UK, PHA-UK. AAH is partially funded by Actelion Ltd. Gewerbestrasse 16CH-4123 Allschwil Switzerland Unit 3A Enterprise Court Farfield ParkManversRotherhamSouth Yorkshire S63 5DB, UK.
Competing interests HF and AAH declare no conflicts, SM has received an honorarium from Actelion Ltd. ISN and SGH have acted as a consultant and received unrestricted educational grants from Actelion Ltd, Encysive pharmaceuticals, GlaxoSmithKline and Pfizer.
Ethics approval This work was approved by the ethics committee of Great Ormond Street Hospital and UCL Institute of Child Health.
Provenance and peer review Not commissioned; externally peer reviewed.